<DOC>
	<DOCNO>NCT01910194</DOCNO>
	<brief_summary>Impact combine Lantus ( insulin glargine ) Lyxumia ( lixisenatide ) insulin secretion gastric empty</brief_summary>
	<brief_title>Impact Combined Lantus ( Insulin Glargine ) Lyxumia ( Lixisenatide ) Insulin Secretion Gastric Emptying</brief_title>
	<detailed_description>Impact combine Lantus ( insulin glargine ) Lyxumia ( lixisenatide ) insulin secretion gastric empty</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients type 2 diabetes mellitus diagnose least one year screen visit previously treat glitazones , insulin GLP1 agonists Inadequately control diabetes mellitus Subjects type 1 diabetes , maturity onset diabetes young ( MODY ) secondary form diabetes due pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>